Prostate cancer with variants in CYP17 and UGT2B17 genes: A meta-analysis

Protein and Peptide Letters

Volumn 19, Issue 1, 2012, Pages 62-69

  Cai, Lai ^a,c   Huang, Wei ^b,c   Chou, Kuo Chen ^c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c GORDON LIFE SCIENCE INSTITUTE   (United States)

Author keywords

CYP17; Meta analysis; Prostate cancer; UGT2B17

Indexed keywords

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CYP17 GENE; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; TUMOR GENE; UGT2B17 GENE;

EID: 84863258926     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986612798472848     Document Type: Article

References (51)

1. Chambers D. C. Prostate cancer and prostate-specific antigen: facts, figures and commentary. J. Insur. Med. 1993, 25, 336-340.
2. Jemal, A.; Murray, T.; Samuels, A.; Ghafoor, A.; Ward, E.; Thun, M. J. Cancer statistics, 2003. Can. Cancer J. Clin., 2003, 53, 5-26.
3. Debes, J. D.; Tindall, D. J. Mechanisms of androgen-refractory prostate cancer. New Engl. J. M., 2004, 351, 1488-1490. (Pubitemid 39315314)
4. Picadoleonard, J.; Miller, W. L. Cloning and sequence of the human-gene for P450C17 (Steroid 17-alpha-hydroxylase/17,20 lyase): Similarity with the gene for P450C21. DNA, 1987, 6, 439-448. (Pubitemid 18085844)
5. Ross, R. K.; Pike, M. C.; Coetzee, G. A.; Reichardt, J. K.; Yu, M. C.; Feigelson, H.; Stanczyk, F. Z.; Kolonel, L. N.; Henderson, B. E. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res., 1998, 58, 4497-4504. (Pubitemid 28480602)
6. Chen, F.; Ritter, J. K.; Wang, M. G.; McBride, O. W.; Lubet, R. A.; Owens, I. S. Characterization of a cloned human dihydrotestos-terone/ androstanediol UDP-glucuronosyltransferase and its comparison to other steroid isoforms. Biochemistry, 1993, 32, 10648-10657. (Pubitemid 23327797)
7. Beaulieu, M.; Levesque, E.; Hum, D. W.; Belanger, A. Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C-19 steroids. J. Biol. Chem., 1996, 271, 22855-22862. (Pubitemid 26304735)
8. Gunes, S.; Bagci, H.; Sarikaya, S.; Bilen, C. Y.; Kara, N. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia. DNA Cell Biol., 2007, 26, 873-878. (Pubitemid 350274412)
9. Cussenot, O.; Azzouzi, A. R.; Nicolaiew, N.; Fromont, G.; Mangin, P.; Cormier, L.; Fournier, G.; Valeri, A.; Larre, S.; Thibault, F.; Giordanella, J. P.; Pouchard, M.; Zheng, Y.; Hamdy, F. C.; Cox, A.; Cancel-Tassin, G. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J. Clin. Oncol., 2007, 25, 3596-3602. (Pubitemid 47376605)
10. Wu, Y. J.; Liang, C. H.; Zhou, F. J.; Gao, X.; Chen, L. W.; Liu, Q. A case-control study of environmental and genetic factors and prostate cancer in Guangdong. Zhonghua Yu Fang Yi Xue Za Zhi, 2009, 43, 581-585.
11. Vesovic, Z.; Herkommer, K.; Vogel, W.; Paiss, T.; Maier, C. Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany. Anticancer Res., 2005, 25, 1303-1307. (Pubitemid 40546806)
12. Ntais, C.; Polycarpou, A.; Ioannidis, J. P. A. Association of the CYP17 gene polymorphism with the risk of prostate cancer: A meta-analysis. Cancer Epidemiol. Biomark. Prev., 2003, 12, 120-126. (Pubitemid 36194001)
13. Habuchi, T.; Zhang, L. Q.; Suzuki, T.; Sasaki, R.; Tsuchiya, N.; Tachiki, H.; Shimoda, N.; Satoh, S.; Sato, K.; Kakehi, Y.; Kamoto, T.; Ogawa, O.; Kato, T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res., 2000, 60, 5710-5713.
14. Woolf, B. On estimating the relation between blood group and disease. Ann. Hum. Genet., 1955, 19, 251-253.
15. Lau, J.; Ioannidis, J. P. A.; Schmid, C. H. Quantitative synthesis in systematic reviews. Ann. Intern. Med., 1997, 127, 820-826. (Pubitemid 27465551)
16. Higgins, J. P. T.; Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med., 2002, 21, 1539-1558. (Pubitemid 34746062)
17. Mantel, N.; Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer I., 1959, 22, 719-748.
18. Dersimonian, R.; Laird, N. Metaanalysis in clinical-Trials. Control Clin. Trials, 1986, 7, 177-188.
19. Irwig, L.; Macaskill, P.; Berry, G.; Glasziou, P. Bias in meta-analysis detected by a simple, graphical test-Graphical test is itself biased. Brit. Med. J., 1998, 316, 470-470.
20. Tajtakova, M.; Pidanicova, A.; Valansky, L.; Lachvac; Nagy, V.; Sivonova, M.; Dobrota, D.; Kliment, J.; Petrovicova, J. Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSAand single nucleotide polymorphism in PSAand CYP17 gene may contribute to early diagnostics of prostate cancer. Neoplasma, 2010, 57, 118-122.
21. Chang, B.L.; Zheng, S.Q.L.; Isaacs, S.D.; Wiley, K.E.; Carpten, J.D.; Hawkins, G.A.; Bleecker, E.R.; Walsh, P.C.; Trent, J.M.; Meyers, D.A.; Isaacs, W.B.; Xu, J.F. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int. J. Cancer, 2001, 95, 354-3597.
22. Haiman, C.A.; Stampfer, M.J.; Giovannucci, E.; Ma, J.; Decalo, N.E.; Kantoff, P.W.; Hunter, D.J. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol. Biomark. Prev., 2001, 10, 743-748. (Pubitemid 32695153)
23. Hamada, A.; Danesi, R.; Price, D.K.; Sissung, T.; Chau, C.; Venzon, D.; Sparreboom, A.; Dahut, W.L.; Figg, W.D. Association of a CYP17 polymorphism with overall survival in caucasian patients with androgen-independent prostate cancer. Urology, 2007, 70, 217-220. (Pubitemid 47371142)
24. Kittles, R.A.; Panguluri, R.K.; Chen, W.D.; Massac, A.; Ahaghotu, C.; Jackson, A.; Ukoli, F.; Adams-Campbell, L.; Isaacs, W.; Dunston, G.M. CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol. Biomark. Prev., 2001, 10, 943-947. (Pubitemid 32844901)
25. Latil, A.G.; Azzouzi, R.; Cancel, G.S.; Guillaume, E.C.; Cochan-Priollet, B.; Berthon, P.L.; Cussenot, O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer, 2001, 92, 1130-1137. (Pubitemid 32861661)
26. Lin, C.C.; Wu, H.C.; Chen, W.C.; Chen, H.Y. Tsai, F.J. CYP17 gene promoter allelic variant is not associated with prostate cancer. Urol. Oncol., 2003, 21, 262-265.
27. Lindstrom, S.; Zheng, S.L.; Wiklund, F.; Jonsson, B.A.; Adami, H.O.; Balter K.A.; Brookes, A.J.; Sun, J.L.; Chang, B.L.; Liu, W.N.; Li, G.; Isaacs, W.B.; Adolfsson, J.; Gronberg, H.; Xu, J.F. Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate, 2006, 66, 1729-1743. (Pubitemid 44893899)
28. Madigan, M.P.; Gao, Y.T.; Deng, J.; Pfeiffer, R.M.; Chang, B.L.; Zheng, S.Q.; Meyers, D.A.; Stanczyk, F.Z.; Xu, J.F.; Hsing, A.W. Cyp17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int. J. Cancer, 2003, 107, 271-275. (Pubitemid 37152909)
29. Onen, I.H.; Ekmekci, A.; Eroglu, M.; Polat, F.; Biri, H. The association of 5 alpha-reductase II(SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol., 2007, 26, 100-107. (Pubitemid 46363875)
30. Sarma, A. V.; Dunn, R. L.; Lange, L. A.; Ray, A.; Wang, Y.; Lange, E. M.; Cooney, K. A. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate, 2008, 68, 296-305 (Pubitemid 351273059)
31. Sobti, R.C.; Onsory, K.; Al-Badran, A.I.; Kaur, P.; Watanabe, M.; Krishan, A.; Mohan, H. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol., 2006, 25, 287-294. (Pubitemid 43830442)
32. Sobti, R.C.; Gupta, L.; Singh, S.K.; Seth, A.; Kaur, P.; Thakur, H. Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Cancer Genet. Cytogen., 2008, 185, 78-85
33. Guli, M.R.;, Wang, J.Q.; Zhang, J.X.; Deng, G. Association between the polymorphism of CYP17 gene and risk of prostate cancer in chinese vigurs men. Zhonghua Nan Ke Xue, 2006, 12, 120-122.
34. Wadelius, M.; Andersson, S.O.; Johansson, J.E.; Wadelius, C.; Rane, A. Prostate cancer associated with CYP17 genotype. Pharmacogenetics, 1999, 9, 635-639.
35. Olsson, M.; Lindstrom, S.; Haggkvist, B.; Adami, H. O.; Balter, K.; Stattin, P.; Ask, B.; Rane, A.; Ekstrom, L.; Gronberg, H. The UGT2B17 gene deletion is not associated with prostate cancer risk. Prostate, 2008, 68, 571-575. (Pubitemid 351500217)
36. Park, J. Y.; Chen, L.; Tanner, J.-P.; Sellers, T.; Lee, J.; Dossett, N.; Ratnashinge, L.; Lang, N.; Kadlubar, F.; Ambrosone, C.; Zachariah, B.; Heysek, R.; Patterson, S.; Pow-Sang, J. The deletion polymorphism of the'UDP-glucuronosyltransferase (UGT) 2B17 and risk of prostate cancer in African American and Caucasian men. Proc. Am. Assoc. Cancer Res. Ann. Meeting, 2006, 47, 865.
37. Park, J.Y; Tanner, J.P.; Sellers, T.A.; Huang, W.; Stevens, C.K.; Dossett, N.; Shankar, R.A.; Zachariah, B.; Heysek, R.; PowSang, J. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology, 2007, 70, 374-379. (Pubitemid 47362236)
38. Karypidis, A.H.; Olsson, M.; Andersson, S.O.; Rane, A.; Ekstrom, L. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J., 2008, 8, 147-151. (Pubitemid 351411551)
39. Setlur, S.R.; Chen, C.X.; Hossain, R.R.; Ha, J.S.; Van, Doren, V.E.; Stenzel, B.; Steiner, E.; Oldridge, D.; Kitabayashi, N.; Banerjee, S.; Chen, J.Y.; Schäfer, G.; Horninger, W.; Lee, C.; Rubin, M.A.; Klocker, H.; Demichelis, F. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol. Biomark. Prev., 2010, 19, 229-239.
40. Gallagher, C.J.; Kadlubar, F.F.; Muscat, J.E.; Arnbrosone, C.B.; Lang, N.P.; Lazarus, P. The UGT2B17 gene deletion polymorphism and risk of prostate cancer-a case-control study in Caucasians. Cancer Detect. Prev., 2007, 31, 310-315. (Pubitemid 47562635)
41. Gronberg, H. Prostate cancer epidemiology. Lancet, 2003, 361, 859-864. (Pubitemid 36331852)
42. Chung, B. C.; Picadoleonard, J.; Haniu, M.; Bienkowski, M.; Hall, P. F.; Shively, J. E.; Miller, W. L. Cytochrome P450C17 (Steroid 17-alpha-hydroxylase/ 17,20 lyase)-Cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc. Natl. Acad. Sci. USA, 1987, 84, 407-411. (Pubitemid 17006204)
43. Chouinard, S.; Pelletier, G.; Belanger, A.; Barbier, O. Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium. Endocrine Res., 2004, 30, 717-725. (Pubitemid 40070159)
44. Ntais, C.; Polycarpou, A.; Ioannidis, J.P.A. Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: A meta-analysis. Cancer Epidemiol. Biomark. Prev, 2005, 14, 176-81. (Pubitemid 40165300)
45. Gronberg, H. Prostate cancer epidemiology. Lancet, 2003, 361, 859-864. (Pubitemid 36331852)
46. Hsing, A.W. Hormones and prostate cancer: what's next? Epidemiol. Rev., 2001, 23, 42-58. (Pubitemid 32906613)
47. Allen, N.E.; Forrest, M.S.; Key, T.J. The association between polymorphisms in the CYP17 and 5 alpha-reductase (SRDRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol. Biomark. Prev., 2001, 10, 185-189. (Pubitemid 34288528)
48. Lazarus, P.; Zheng, Y.; Runkle, E. A.; Muscat, J. E.; Wiener, D. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet. Genom., 2005, 15, 769-778. (Pubitemid 41531726)
49. Olsson, M.; Ekström, L.; Guillemette, C.; Belanger, A.; Rane, A.; Gustafsson, O. Correlation between circulatory, local prostatic, and intra-prostatic androgen levels. Prostate, 2011, 71(9), 909-914.
50. Chou, K.C. Some remarks on protein attribute prediction and pseudo amino acid composition. J. Theor. Biol., 2011, 273(1), 236-247.
51. Chou, K. C.; Shen, H. B. Review: recent advances in developing web-servers for predicting protein attributes. Natural Science, 2009, 2, 63-92.